Fig 1.
Patient disposition in (A) the single-dose and multiple-dose dose-escalation phases and (B) the multiple-dose expansion phase. Represents the safety analysis set. AE = adverse event.
Fig 2.
The first dose in the multiple-dose dose-escalation phase was administered after the third dose level of the single-dose dose-escalation phase (0.2 mg/kg) was evaluated by a study safety group; thereafter, the single- and multiple-dose dose-escalation phases were performed in parallel.
Table 1.
Patient and Disease Characteristics for Patients Receiving Single Doses.
Table 2.
Patient and Disease Characteristics for Patients Receiving Multiple Doses.
Table 3.
Treatment-Emergent AEs by Organ Class Occurring in >1 Patient in Any Study Group.
Fig 3.
Mean anti‒IL-20 serum concentration-time profiles.
Mean serum concentration-time profiles following (A) single dosing or (B) multiple dosing in the dose-escalation phase and individual anti‒IL-20 serum concentration-time profiles following multiple dosing in (C) the expansion phase on a semi-logarithmic scale in patients with psoriasis.
Table 4.
Summary of Pharmacokinetic Parameters After Dosing With Anti‒IL-20.
Fig 4.
Mean PASI total score by visit.
Mean PASI total score by visit following (A) single dosing or (B) multiple dosing in the dose-escalation phase and (C) multiple dosing in the expansion phase. PASI = Psoriasis Area and Severity Index.
Fig 5.
Histology image from a single patient.
Patient from the expansion phase treated with anti‒IL-20. By week 15, this patient experienced marked improvement in epidermal hyperplasia and acanthosis, a large reduction in keratin 16, associated reductions in proliferating keratinocytes (Ki67), and marked reductions in CD11c+ dendritic cells. CD11c = integrin alpha X chain protein; H&E = hematoxylin and eosin stain; K16 = keratin 16; Ki67 = cellular marker for proliferation; NL = nonlesional (skin); LS = longitudinal section.